 |
|
 |
 |
|
WEDNESDAY,
AUGUST 1, 2007
Advances
in Immunotherapy
for Malignant
Melanoma
A
complimentary
dinner meeting
Houston, Texas
Chair:
Agop Y. Bedikian,
MD
MD Anderson Cancer
Center
Houston, Texas
*FULL* |
 |
|
F A C
U L T
Y |
 |
|
|
Agop
Y.
Bedikian,
MD
MD
Anderson
Cancer
Center
Houston,
Texas |
Tyler
J.
Curiel,
MD,
MPH
University
of
Texas
Health
Science
Center
at
San
Antonio
San
Antonio,
Texas |
Joseph
W.
Fay,
MD
Baylor
Institute
for
Immunology
Research
Dallas,
Texas |
|
|
|
S C I
E N T
I F I
C
A G E
N D A
|
|
|
|
6:00
pm
Registration
and
reception
6:30
pm
Introduction
to
the
biology
of
melanoma
Agop
Y.
Bedikian,
MD
6:45
pm
Immunotherapy:
Harnessing
the
immune
response
to
cancer
Tyler
J.
Curiel,
MD,
MPH
7:15
pm
Overcoming
immunologic
tolerance
to
melanoma:
Targeting
CTLA-4
Agop
Y.
Bedikian,
MD
7:45
pm
Enhancing
the
immune
response
to
melanoma:
Vaccines
and
other
novel
biologics
to
stimulate
and
target
the
immune
response
Joseph
W.
Fay,
MD
8:15
pm
Question
and
answer
session
8:30
pm
Adjourn |
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
|
Imedex
Accreditation
Services,
LLC
is
accredited
by
the
Accreditation
Council
for
Continuing
Medical
Education
to
provide
continuing
medical
education
for
physicians.
Imedex
Accreditation
Services,
LLC
designates
this
educational
activity
for
a
maximum
2.0
of
AMA
PRA
Category
1
Credit(s)TM.
Physicians
should
only
claim
credit
commensurate
with
the
extent
of
their
participation
in
the
activity. |
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This
educational
activity
is
specifically
designed
for
medical
oncologists,
dermatologists,
and
other
physicians,
physicians-in-training,
and
healthcare
professionals
interested
in
and/or
involved
in
the
care
of
patients
with
melanoma
and
its
consequences.
No
specialized
knowledge
or
skill
other
than
general
familiarity
with
internal
medicine,
oncology,
or
dermatology
is
required
for
successful
participation
in
this
activity.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
After
successfully
completing
this
educational
activity,
participants
should
be
able
to:
- Describe
the
basic concepts
of immunotherapy
and how
each type
can be
used as
a treatment modality in
oncology
-
Discuss
the
role
immune
tolerance
plays
in
allowing
the
growth
and
spread
of
cancer
cells
-
Explain
the
specific
role
of
CTLA-4
in
maintaining
immune
tolerance
and
how
inhibiting
its
function
can
be
used
in
the
treatment
of
malignant
melanoma
-
Compare
and
contrast
emerging
biological
agents,
primarily
vaccines
and
cytokines,
that
are
used
to
stimulate
and
target
a
patient’s
own
immune
response
against
a
tumor
and
are
currently
in
trials
for
use
against
melanoma
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
*FULL*
You
may
register
online
by
July
31,
2007
or
by
calling
Imedex
at
+1
(678)
242
0906.
Registration
confirmations
will
be
issued
before
the
meeting.
This
is
a
complimentary
dinner
meeting
and
space
is
limited.
To
confirm
your
attendance,
please
register
by
July
31,
2007.
|
|
|
|
G
E N E
R A L
I N F
O R M
A T I
O N |
|
|
|
Meeting
Location
b
i
s t r o m o d e r n e
(in the Hotel Derek)
2525 west loop south
Houston, Texas 77027
Tel: 713-297-4383 |
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2007 Imedex Accreditation
Services, LLC.
All rights reserved.
Reproduction in
whole or part
is prohibited
without prior
written consent
from Imedex and
contributing faculty. |
